|Target||Angiopoietin-like 3 (ANGPTL3)|
|subcutaneously (SC) or intravenously (IV)|
|Chemical and physical data|
|Molar mass||146.1 kg/mol g·mol−1|
This drug was developed by Regeneron Pharmaceuticals, Inc. In phase 1, first-in-human, ascending single-dose, placebo (PBO)-controlled, double-blind study evaluated the safety and efficacy of evinacumab administered subcutaneously (SC) or intravenously (IV) in subjects with elevated TGs (150≤ TG ≤450 mg/dL) and/or LDL-C (≥100 mg/dL). Evinacumab effected dose-responsive reductions in TG (maximum reduction on Day 4) with median % changes from baseline of -1.0% to -75.0% from low to high dose vs +9.0% for PBO IV [p<0.0001]) and LDL-C (mean % changes of LDL-C from baseline on Day 11 were -3.4% to -25.5% from low to high dose vs -0.4% for PBO IV [p=0.0013]).
|This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.|